US 11033626
Progesterone formulations having a desirable pk profile
granted A61KA61K31/57A61K47/14
Quick answer
US patent 11033626 (Progesterone formulations having a desirable pk profile) held by Compass Therapeutics LLC expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Compass Therapeutics LLC
- Grant date
- Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/57, A61K47/14, A61K9/4825, A61K9/4858